Pancreatic cancer is a tumor type with a poor prognosis, and researchers have not yet developed an effective treatment for this cancer, and recently, an article published in the international journal Nature Cancer titled "Selective multi-kinase inhibition sensitizes mesenchymal." In the pancreatic cancer to immune checkpoint blockade by remodeling the tumor microenvironment, scientists from the German Cancer Research Center and other institutions have found a new way to conduct preclinical studies on mouse models, which may be able to use the targeted combination of two cancer drugs to make immunotherapy more effective in treating pancreatic tumors. The researchers believe that this potential combination strategy may also be effective in treating other types of cancer.
![outburst! Tesla raised the price again, did you regret not being able to pick up the car in "last year"?[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)